Medpace Holdings guidance update and why it matters now

Medpace Holdings (MEDP) recently updated its 2026 guidance, telling investors to expect revenue of about $2.805b to $2.885b, net income of $494m to $514m, and earnings per diluted share of $17.25 to $17.95.

This fresh outlook, which the company has characterized as implying double digit revenue growth compared with 2025 figures and higher projected earnings, gives you a current reference point for thinking about how the stock’s recent performance lines up with the company’s own expectations.

The guidance comes as Medpace Holdings trades at US$587.75, with a 90 day share price return of 37.10% and a 1 year total shareholder return of 36.57%, which suggests recent momentum has been strong on both a short and multi year view.

If this updated outlook has you thinking about where else growth stories might be emerging in healthcare, it could be a good time to broaden your research through the 42 healthcare AI stocks

After a 37.10% move over 90 days and guidance that points to higher 2026 earnings, the real question for Medpace Holdings now is whether most of the rerating is already priced in or if valuation still leaves room.

Most Popular Narrative: 28.9% Overvalued

Against Medpace Holdings' last close at $587.75, the most followed narrative points to a fair value of $456.00, which implies a sizeable valuation gap that investors are weighing against the latest guidance.

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive, which could result in lower underlying revenue and EBITDA growth once this project mix normalizes.

Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside; should the improved funding or lower cancellations reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.

Want to see what sits behind that fair value of $456.00 for Medpace Holdings? The narrative leans on specific revenue growth, margin expansion, and future earnings multiple assumptions. Curious which combination of top line compounding, margin profile, and required return needs to hold for that number to make sense? The full story joins those pieces together and shows exactly how they translate into today’s valuation call.

Result: Fair Value of $456.00 (OVERVALUED)

However, if clinical trial demand stays robust and Medpace Holdings maintains margin efficiency despite higher hiring and costs, the current overvaluation narrative could be challenged.

Another view on Medpace Holdings valuation

The narrative fair value of $456.00 paints Medpace Holdings as 28.9% overvalued. Yet a separate check using the Simply Wall St DCF model suggests a fair value of $658.31, which is about 10.7% above the current $587.75 share price. Which framework do you trust more when the signals disagree?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medpace Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between risks and rewards around Medpace Holdings, this is a moment to move quickly and weigh the evidence for yourself. To see how investors are balancing both sides of the story, review the 3 key rewards and 1 important warning sign

Looking for more Medpace Holdings sized opportunities?

If Medpace Holdings has sharpened your focus, do not stop here. The screener can quickly surface other ideas that fit your style before the market moves on.

• Target quality at a discount and scan for companies that might trade below their estimated worth using the 51 high quality undervalued stocks.
• Prioritise resilience and check out companies that pair stronger balance sheets with solid fundamentals through the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for future standouts early by reviewing the screener containing 17 high quality undiscovered gems that the market may not be focusing on yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.